what this node claims
Initial digest — OXTR
AlphaFold v6 prediction landed for **OXTR** (Oxytocin receptor). UniProt accession: `P30559`. Lane: `sexual_wellbeing`. Mean per-residue pLDDT: **78.62**. _(no notes)_
vertical proof spine
evidence / risk instrument
39%
low debt pressure
29%
28%structuredebt
pLDDT pending
55%evidencethin
grade C
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
33%lineagedebt
incomplete spine
proof completeness
33% missing target, alphafold_metric, candidate, export- 01 target
- 02 fold
- 03 alphafold metric
- 04 candidate
- 05 finding
- 06 export
Metrics and receipt inputs
- confidence
- 0.6
- evidence refs
- 1
AlphaFold metrics visual
Confident backbone model
389 residues / min 24.28 / max 98.81 / source alphafold db
Very high
51.9%
202 residues / >=90
Confident
19.8%
77 residues / 70-89
Low
11.3%
44 residues / 50-69
Very low
17.0%
66 residues / <50
usable fold context with explicit model-confidence limits
Near-complete coverage / observed 389 of 389 residues.
- residues 346-389 / mean 42.63
- residues 1-34 / mean 34.62
- residues 243-264 / mean 56.55
- residues 306-314 / mean 63.75
proof debt register
29%
Visible limits, not hidden cleanup.
Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.